Live Breaking News & Updates on Il 36

Stay updated with breaking news from Il 36. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Spesolimab for Treatment of Generalized Pustular Psoriasis (GPP) Flares

Dermatologists Drs Tina Bhutani and Scott Boswell discuss use of spesolimab to treat generalized pustular psoriasis (GPP) flares. ....

Tina Bhutani , J Scott Boswell , Kanya Oul , Generalized Pustular Psoriasis , Inflammatory Disease , Gpp Flares , Systemic Disease , Il 36 , Subcutaneous Injection , Maintenance Therapy ,

Use of Biologics in Rare Dermatologic Disorders

Experts discuss the use of biologics in the treatment of rare dermatologic disorders. ....

Identifying Rare Dermatologic Disorders , Critical Care Setting , Rare Dermatologic , Rare Dermatological Disorders , Il 36 , Il 36 Inhibitors , Il 17 Inhibitors , Tnf Alpha Inhibitors ,

Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares

EFFISAYIL™ 2 met its primary and key secondary endpoint, demonstrating that spesolimab, an anti-interleukin-36 receptor antibody, can prevent flares in adolescents and adults with generalized pustular psoriasis (GPP) up to 48 weeks.1,2 ....

Rheinland Pfalz , Laura Lessenich , Carinne Brouillon , European Union , Corporate Communications , Boehringer Ingelheim , Managing Directors , Human Pharma , Mainland China , Media Contact , Ffisayil 2 , Generalized Pustular Psoriasis , Clinical Trials , Carinne Brouillon , Human Pharma , Rare Skin Disease , Plaque Psoriasis , Gpp Flares , Nterleukin 36 Receptor , Il 36 , Ffisayil 1 , Ffisayil On ,